Johnson & Johnson announced that its subcutaneous (SC) formulation of Amivantamab has now been authorized for all indications previously approved for intravenous (IV) Amivantamab.
Show original
This authorization means that the application scope of the drug has been officially expanded under a more convenient administration method.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Exclusive Article for Futures Monitoring Tool
金十•2026/03/05 00:28
Broadcom sees the surge in AI demand as a long-term trend
格隆汇•2026/03/05 00:22
Today's Fear and Greed Index rises to 22, still classified as Extreme Fear
金色财 经•2026/03/05 00:19
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$72,943.49
+6.65%
Ethereum
ETH
$2,133.6
+7.52%
Tether USDt
USDT
$1
+0.00%
BNB
BNB
$658.59
+3.87%
XRP
XRP
$1.43
+5.15%
USDC
USDC
$1.0000
-0.01%
Solana
SOL
$91.27
+4.55%
TRON
TRX
$0.2874
+2.84%
Dogecoin
DOGE
$0.09848
+9.32%
Cardano
ADA
$0.2747
+4.45%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now